Actinium Pharmaceuticals (ATNM) investor relations material

Executive summary

• Focused on developing targeted radiotherapies for oncology, with a pipeline including ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT across solid tumors and hematologic malignancies.

• ATNM-400 demonstrated pan-tumor preclinical efficacy in prostate, lung, and breast cancer models, outperforming current standards in resistant settings.

• Actimab-A is positioned as a backbone therapy for AML/MDS and as an immunomodulatory agent in solid tumors, with ongoing and planned clinical trials.

• Iomab-B and Iomab-ACT are being developed as targeted conditioning agents for bone marrow transplant and cell/gene therapies, with clinical trials ongoing.

Financial highlights

• Net loss for Q1 2026 was $5.5 million, a significant improvement from $15.9 million in Q1 2025, driven by lower R&D and G&A expenses.

• Research and development expenses decreased to $4.2 million from $7.7 million year-over-year, reflecting lower stock-based compensation and reduced headcount.

• General and administrative expenses fell to $1.7 million from $8.9 million, mainly due to lower stock-based compensation.

• Cash, cash equivalents, and restricted cash totaled $42.5 million as of March 31, 2026, down from $48.3 million at year-end 2025.

• No commercial or grant revenue recognized in Q1 2026; $35 million in deferred license revenue remains contingent on EU regulatory approval for Iomab-B.

Outlook and guidance

• Existing resources expected to fund operations for more than 12 months from the report date.

• Initial data from the Actimab-A/PD-1 inhibitor basket trial expected in 2H 2026 or 1H 2027.

• Actively seeking strategic partners for pivotal trials and commercialization of Actimab-A and Iomab-B in the U.S.